Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer.
| FactSnippet No. 737,067 |
10 Facts About Rituximab
2.
Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells.
| FactSnippet No. 737,068 |
3.
Rituximab is a chimeric monoclonal antibody targeted against CD20 which is a surface antigen present on B cells.
| FactSnippet No. 737,069 |
4.
Rituximab is used to treat cancers of the white blood system such as leukemias and lymphomas, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and nodular lymphocyte predominant Hodgkin's lymphoma.
| FactSnippet No. 737,070 |
5.
Rituximab has been shown to be an effective rheumatoid arthritis treatment in three randomised controlled trials and is licensed for use in refractory rheumatoid disease.
| FactSnippet No. 737,071 |
6.
Rituximab has been reported as a possible cofactor in a chronic hepatitis E infection in a person with lymphoma.
| FactSnippet No. 737,072 |
7.
Rituximab is relatively ineffective in elimination of cells with low CD20 cell-surface levels.
| FactSnippet No. 737,073 |
8.
Rituximab leads to a reduced function of B cells as antigen presenting cells and, by increasing immature and transitional B cells, to a dysfunction of CD4+ T cells and abnormal cytotoxic T-cell-specific responses.
| FactSnippet No. 737,074 |
9.
Rituximab is co-marketed by Biogen and Genentech in the U S, by Hoffmann-La Roche in Canada and the European Union, Chugai Pharmaceuticals, Zenyaku Kogyo in Japan and AryoGen in Iran.
| FactSnippet No. 737,075 |
10.
Rituximab did not improve symptoms in patients with chronic fatigue syndrome in a trial published in 2019.
| FactSnippet No. 737,076 |